Context Therapeutics, a clinical-stage biotechnology company, today announced that new preclinical data on CTX-30916, a new PR antagonist, will be featured at the upcoming AACR Annual Meeting taking place in Atlanta, Georgia on April 1, 2019 .

Context Therapeutics, a clinical-stage biopharmaceutical company dedicated to the treatment of hormone-responsive cancers, today announced two key additions to its board of directors. 

Deepak Lala, Tasir Haque, Hannah Feinman, Jianhong Wu, Yuren Wang, Amy Dwyer, Thu Truong and Carol Lange